Binu Aditya John, Kapoor Nitin
Department of Cardiology, Christian Medical College Vellore, Tamil Nadu, India.
Department of Endocrinology, Diabetes and Metabolism, Christian Medical College, Vellore, Tamil Nadu, India.
Heart Int. 2024 May 22;18(1):3-4. doi: 10.17925/HI.2024.18.1.1. eCollection 2024.
Semaglutide is a glucagon-l ike peptide 1 receptor agonist that has been noted to have a significant role in the reduction of body weight and glycaemic control. An increasing body of evidence from recent trials (SUSTAIN-6, SELECT and STEP HF) has shown significant cardiovascular benefits of semaglutide in both patients with and without diabetes and in people who are obese or overweight. Additional studies in a more diverse patient population and safety assessment are warranted prior to adding semaglutide to the increasing pool of guideline-directed medical therapy for the treatment and prevention of cardiac diseases.
司美格鲁肽是一种胰高血糖素样肽1受体激动剂，已被注意到在减轻体重和控制血糖方面发挥着重要作用。最近的试验（SUSTAIN - 6、SELECT和STEP HF）越来越多的证据表明，司美格鲁肽对糖尿病患者和非糖尿病患者以及肥胖或超重人群都有显著的心血管益处。在将司美格鲁肽添加到越来越多的用于治疗和预防心脏病的指南指导药物治疗方案之前，有必要在更多样化的患者群体中进行进一步研究和安全性评估。
